ThromboGenics to Change Name to Oxurion

June 29, 2018: By Jon Swedien

ThromboGenics intends to change its name to “Oxurion,” the Belgium company announced June 27.

Shareholders will be asked to approve the move July 27.

The change would take effect Sept. 10 and alter the company’s stock ticker symbol from “THR” to “OXUR.”

Oxurion is derived from the words oxygen and Orion, a Greek mythological figure who had his sight restored after being blinded, ThromboGenics said.

ThromboGenics is focused on back of the eye diseases, with a pipeline in diabetic eye disease. The company owns the global rights to Jetrea (ocriplasmin), which is approved for symptomatic vitreomacular adhesion in the US and vitreomacular traction outside the US. The company’s clinical pipeline includes:

–THR-317, a PlGF inhibitor, which is in an ongoing Phase III study in combination Lucentis for the treatment of diabetic macular edema (DME).

–THR-149, a plasma kallikrein inhibitor, which is in a Phase I clinical study for DME.

–THR-687, an integrin antagonist, which is in preclinical development for the treatment of diabetic retinopathy and DME. It is expected to enter the clinic in mid-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales